![Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Neurology Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Neurology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/c9607895-9cd2-435b-a940-09e00fd2d3d2/gr1_lrg.gif)
Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Neurology
![High‐dose biotin restores redox balance, energy and lipid homeostasis, and axonal health in a model of adrenoleukodystrophy - Fourcade - 2020 - Brain Pathology - Wiley Online Library High‐dose biotin restores redox balance, energy and lipid homeostasis, and axonal health in a model of adrenoleukodystrophy - Fourcade - 2020 - Brain Pathology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/526cd5f6-a354-4c16-a999-f0ad0dc4d563/bpa12869-fig-0005-m.jpg)
High‐dose biotin restores redox balance, energy and lipid homeostasis, and axonal health in a model of adrenoleukodystrophy - Fourcade - 2020 - Brain Pathology - Wiley Online Library
![Could High-Dose Biotin Be Used as a Treatment for Multiple Sclerosis? - Multiple Sclerosis News Today Could High-Dose Biotin Be Used as a Treatment for Multiple Sclerosis? - Multiple Sclerosis News Today](https://multiplesclerosisnewstoday.com/wp-content/uploads/2017/07/high-biotin-ms.png)
Could High-Dose Biotin Be Used as a Treatment for Multiple Sclerosis? - Multiple Sclerosis News Today
![Phase III Study of Experimental MS Therapy Meets Primary Endpoint, Results to be Presented at ANN Meeting Phase III Study of Experimental MS Therapy Meets Primary Endpoint, Results to be Presented at ANN Meeting](https://multiplesclerosisnewstoday.com/wp-content/uploads/2015/04/blue-neuron.jpg)
Phase III Study of Experimental MS Therapy Meets Primary Endpoint, Results to be Presented at ANN Meeting
![MedDay Reports Top-Line Data from Phase III Trial “SPI2” for Treatment of Progressive Forms of Multiple Sclerosis | Business Wire MedDay Reports Top-Line Data from Phase III Trial “SPI2” for Treatment of Progressive Forms of Multiple Sclerosis | Business Wire](https://mms.businesswire.com/media/20200310005779/en/778854/23/MedDay_Logo.jpg)
MedDay Reports Top-Line Data from Phase III Trial “SPI2” for Treatment of Progressive Forms of Multiple Sclerosis | Business Wire
![MedDay Pharmaceuticals Announces Full Patient Enrollment for MD1003 Phase III Clinical Trial (SPI2) in Progressive Multiple Sclerosis | Business Wire MedDay Pharmaceuticals Announces Full Patient Enrollment for MD1003 Phase III Clinical Trial (SPI2) in Progressive Multiple Sclerosis | Business Wire](https://mms.businesswire.com/media/20181109005153/en/689384/22/MedDay_logo.jpg)
MedDay Pharmaceuticals Announces Full Patient Enrollment for MD1003 Phase III Clinical Trial (SPI2) in Progressive Multiple Sclerosis | Business Wire
Pharmacokinetics and pharmacodynamics of MD1003 (high-dose biotin) in the treatment of progressive multiple sclerosis: Expert Opinion on Drug Metabolism & Toxicology: Vol 12, No 3
Andy Biotech on Twitter: "MedDay high dose biotin MD1003 Ph3 data in Progressive MS at #AAN15 http://t.co/FascW4Vfme @lomu_j @hydrogenblimp @Sport234a @jq1234t" / Twitter
![High-dose pharmaceutical grade biotin (MD1003) in amyotrophic lateral sclerosis: A pilot study - EClinicalMedicine High-dose pharmaceutical grade biotin (MD1003) in amyotrophic lateral sclerosis: A pilot study - EClinicalMedicine](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/c70c6ff6-6e0c-4849-a9ec-93b2ad26ce52/gr1.jpg)